Details

Autor(en) / Beteiligte

• Gorringe, Kylie L
• Hunter, Sally M
• Pang, Jia-Min
• Opeskin, Ken
• Hill, Prue
• Rowley, Simone M
• Choong, David Y H
• Thompson, Ella R
• Dobrovic, Alexander
• Fox, Stephen B
• Mann, G Bruce
• Campbell, Ian G

Titel

Copy number analysis of ductal carcinoma in situ with and without recurrence

Ist Teil von

• Modern pathology, 2015-09, Vol.28 (9), p.1174-1184

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2015

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer and a frequent mammographic finding requiring treatment. Up to 25% of DCIS can recur and half of recurrences are invasive, but there are no reliable biomarkers for recurrence. We hypothesised that copy number aberrations could predict likelihood of recurrence. We analysed a cohort of pure DCIS cases treated only with wide local excision for genome-wide copy number and loss of heterozygosity using Affymetrix OncoScan MIP arrays. Cases included those without recurrence within 7 years (n = 25) and with recurrence between 1 and 5 years after diagnosis (n = 15). Pure DCIS were broadly similar in copy number changes compared with invasive breast cancer, with the consistent exception of a greater frequency of ERBB2 amplification in DCIS. There were no significant differences in age or ER status between the cases with a recurrence vs those without. Overall, the DCIS cases with recurrence had more copy number events than the DCIS without recurrence. The increased copy number appeared non-random with several genomic regions showing an increase in frequency in recurrent cases, including 20 q gain, ERBB2 amplification and 15q loss. Copy number changes may provide prognostic information for DCIS recurrence, but validation in additional cohorts is required.